Patents by Inventor Jacob M. Hoffman, Jr.

Jacob M. Hoffman, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tyrosine kinase inhibitors
    Patent number: 7115597
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: October 3, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Jacob M. Hoffman, Jr., John T. Sisko, Peter J. Manley, Anthony M. Smith, Thomas J. Tucker, William C. Lumma, Jr., Leonard Rodman
  • Inhibitors of HIV reverse transcriptase
    Patent number: 5527819
    Abstract: Novel indole compounds inhibit HIV reverse transcriptase, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 18, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Theresa M. Williams, Terrence M. Ciccarone, Walfred S. Saari, John S. Wai, William J. Greenlee, Suresh K. Balani, Mark E. Goldman, Anthony D. Theoharides, deceased, Jacob M. Hoffman, Jr., William C. Lumma, Jr., Joel R. Huff, Clarence S. Rooney, Philip E. Sanderson
  • Inhibitors of HIV reverse transcriptase
    Patent number: 5308854
    Abstract: Novel aminopyridones inhibit HIV reverse transcriptase, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: November 4, 1992
    Date of Patent: May 3, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Jacob M. Hoffman, Jr., Walfred S. Saari, Clarence S. Rooney, John S. Wai
  • Heterobicyclic sulfonamides
    Patent number: 5276025
    Abstract: Compounds of general formula: ##STR1## are topically effective carbonic anhydrase inhibitors useful in the treatment of ocular hypertension and related disorders such as glaucoma.
    Type: Grant
    Filed: September 9, 1992
    Date of Patent: January 4, 1994
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Jacob M. Hoffman, Jr., James H. Jones, Clarence S. Rooney, Anthony M. Smith
  • 4-(2-methyl-2-hydroxypropylamino)-5,6-dihydrot hieno-[2,3-b]thiopyran-2-sulfonamide-7,7-dioxide
    Patent number: 4946859
    Abstract: 4-(2-Methyl-2-hydroxypropylamino)-5,6-dihydrothieno[2,3-b]thiopyran-2-sulfo namide-7,7-dioxide is a major mammalian metabolite of 4-(2-methylpropylamino)-5,6-dihydrothieno[2,3-b]thiopyran-2-sulfonamide-7, 7-dioxide and is itself an active carbonic anhydrase inhibitor useful in the treatment of ocular hypertension by topical administration.
    Type: Grant
    Filed: July 31, 1989
    Date of Patent: August 7, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Jacob M. Hoffman, Jr., Ling L. Lee, Sandor L. Varga, Anthony G. Zacchei
  • Furopyridine sulfonamides and their opthalmological compositions
    Patent number: 4808595
    Abstract: Furopyridine sulfonamides are carbonic anhydrase inhibitors useful in the treatment of elevated intraocular pressure and disorders associated therewith such as glaucoma.
    Type: Grant
    Filed: May 5, 1988
    Date of Patent: February 28, 1989
    Assignee: Merck & Co., Inc.
    Inventor: Jacob M. Hoffman, Jr.
  • Thienopyridine sulfonamides and their ophthalmological formulation
    Patent number: 4731368
    Abstract: Thienopyridine sulfonamides are carbonic anhydrase inhibitors useful in the treatment of elevated intraocular pressure and disorders associated therewith such as glaucoma.
    Type: Grant
    Filed: December 8, 1986
    Date of Patent: March 15, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Jacob M. Hoffman, Jr., Kenneth L. Shepard
  • Ethers of hydroxybenzothiazole-2-sulfonamide for the topical treatment of elevated intraocular pressure
    Patent number: 4505923
    Abstract: Novel ethers of hydroxy-2-benzothiazolesulfonamide are useful for the topical treatment of elevated intraocular pressure. Ophthalmic compositions include drops and inserts.
    Type: Grant
    Filed: October 31, 1983
    Date of Patent: March 19, 1985
    Assignee: Merck & Co., Inc.
    Inventors: Jacob M. Hoffman, Jr., Otto W. Woltersdorf, Jr.
  • Thiatriazine dioxides as gastric anti-secretory agents
    Patent number: 4497810
    Abstract: There are disclosed novel 1,2,4,6-thiatriazine-1,1-dioxides and related compounds which are connected to a substituted phenyl or heterocyclic group through a linear or cyclic connecting group. Processes are provided for the preparation of such compounds. The compounds are useful for the suppression of gastric acid secretions in mammals and compositions for such uses are also disclosed.
    Type: Grant
    Filed: October 14, 1983
    Date of Patent: February 5, 1985
    Assignee: Merck & Co., Inc.
    Inventor: Jacob M. Hoffman, Jr.
  • Process for preparing sulfamylamidine antisecretory agents
    Patent number: 4496737
    Abstract: A process is disclosed for preparing intermediates which are useful for obtaining sulfamylamidine antisecretory agents.
    Type: Grant
    Filed: September 27, 1982
    Date of Patent: January 29, 1985
    Assignee: Merck & Co., Inc.
    Inventor: Jacob M. Hoffman, Jr.
  • Substituted pyridopyrimidines as gastric secretion inhibitors
    Patent number: 4420615
    Abstract: There are disclosed novel substituted pyridopyrimidine compounds and processes for preparing such compounds. These compounds are useful as gastric secretion inhibitors in mammals.
    Type: Grant
    Filed: August 24, 1981
    Date of Patent: December 13, 1983
    Assignee: Merck & Co., Inc.
    Inventors: William A. Bolhofer, Edward J. Cragoe, Jacob M. Hoffman, Jr
  • Substituted naphthyridinones and processes for their preparations
    Patent number: 4229456
    Abstract: Organic chemical compounds based upon the naphthyridine molecule are disclosed which have potent gastric secretion inhibitory properties. The naphthyridinone is substituted with a substituted amino alkyl group at the 1-position, and variously substituted at the remaining positions. The compounds have profound effects on the inhibition of gastric secretions in the gastro-intestinal tract, and compositions for such uses are also disclosed.
    Type: Grant
    Filed: October 23, 1978
    Date of Patent: October 21, 1980
    Assignee: Merck & Co., Inc.
    Inventors: William A. Bolhofer, Edward J. Cragoe, Jr., Jacob M. Hoffman, Jr.
  • Cyclic imidazole cyanoguanidines
    Patent number: 4220654
    Abstract: There are disclosed novel compounds described as imidazole cyanoguanidines in which the imidazole moiety is connected to the cyanoguanidine moiety through a cyclic group which may optionally contain one or two alkylene linkages. The cyclic groups may be phenyl, cyclohexyl, thienyl and the like. Processes for the preparation of such compounds are also disclosed. The compounds are useful for the suppression of gastric acid secretion in mammals, and compositions for such uses are also disclosed.
    Type: Grant
    Filed: June 4, 1979
    Date of Patent: September 2, 1980
    Assignee: Merck & Co., Inc.
    Inventors: William A. Bolhofer, Edward J. Cragoe, Jr., Jacob M. Hoffman, Jr.
  • Pyridinyl ureas and pharmaceutical use
    Patent number: 4203988
    Abstract: Compounds of the formula ##STR1## have been found to inhibit gastric secretion in mammalian species.
    Type: Grant
    Filed: September 18, 1978
    Date of Patent: May 20, 1980
    Assignee: Merck & Co., Inc.
    Inventors: William A. Bolhofer, Edward J. Cragoe, Jr., Jacob M. Hoffman, Jr.
  • Substituted naphthyridinones
    Patent number: 4133885
    Abstract: Organic chemical compounds based upon the naphthyridine molecule are disclosed which have potent gastric secretion inhibitory properties. The naphthyridinone is substituted with a substituted amino alkyl group at the 1-position, and variously substituted at the remaining positions. The compounds have profound effects on the inhibition of gastric secretions in the gastro-intestinal tract, and compositions for such uses are also disclosed.
    Type: Grant
    Filed: July 18, 1977
    Date of Patent: January 9, 1979
    Assignee: Merck & Co., Inc.
    Inventors: William A. Bolhofer, Edward J. Cragoe, Jr., Jacob M. Hoffman, Jr.